MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317384 | Name: Cefdinir free base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefdinir free base is a semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefdinir's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefdinir inhibits bacterial septum and cell wall synthesis formation.

Chemical Structure

Cefdinir free base
Cefdinir free base
CAS#91832-40-5 (free base)

Theoretical Analysis

MedKoo Cat#: 317384

Name: Cefdinir free base

CAS#: 91832-40-5 (free base)

Chemical Formula: C14H13N5O5S2

Exact Mass: 395.0358

Molecular Weight: 395.41

Elemental Analysis: C, 42.53; H, 3.31; N, 17.71; O, 20.23; S, 16.22

Price and Availability

Size Price Availability Quantity
1g USD 350.00 2 Weeks
2g USD 550.00 2 Weeks
5g USD 1,050.00 2 Weeks
10g USD 1,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
91832-40-5 (free base) 213978-34-8 (hydrate)
Synonym
PD 134393; PD-134393; PD134393; Cefdinir; Omnicef; CFDN; Cefdinirum; Cefdinyl; CI 983; CI-983; FK 482; FK-482; Omnicef.
IUPAC/Chemical Name
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
InChi Key
RTXOFQZKPXMALH-GHXIOONMSA-N
InChi Code
InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1
SMILES Code
C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\O)/C3=CSC(=N3)N)SC1)C(=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Cefdinir (FK 482, PD 134393, CI-983) is an oral cephalosporin antibiotic, used to treat bacterial infections in many different parts of the body.
In vitro activity:
Cefdinir, a new oral 2-amino-5-thiazolyl cephalosporin, inhibited the luminol-amplified chemiluminescence (LACL) response of human neutrophils stimulated by PMA but not opsonized zymosan, in a concentration-dependent but not time-dependent manner. The LACL response to opsonized zymosan in cytochalasin B-treated neutrophils was, however, inhibited by cefdinir. Various cephalosporins, regardless of the presence of a 2-amino-5-thiazolyl moiety, did not significantly alter the neutrophil LACL response triggered by PMA and zymosan. The LACL response induced by the calcium ionophore A23187 and FMLP was also impaired by cefdinir, and this impairment was increased in cytochalasin B-treated neutrophils. Superoxide anion generation by neutrophils, measured in terms of lucigenin-amplified chemiluminescence and cytochrome c reduction, was not altered. Spontaneous and FMLP-induced neutrophil degranulation, assessed by lysozyme and beta-glucuronidase release, were not modified by cefdinir. Furthermore, cefdinir inhibited LACL generation in cell-free systems consisting of H2O2, NaI, and either horseradish peroxidase or a myeloperoxidase-containing neutrophil extract. Orthodianisidine oxidation in these two acellular systems was inhibited by cefdinir. Cefdinir did not alter neutrophil bacterial killing at concentrations that inhibited myeloperoxidase-containing neutrophil extract-dependent reactions induced by soluble stimuli. Taken together, these data strongly suggest that cefdinir directly inhibits the activity of myeloperoxidase-containing neutrophil extract released into the extracellular medium during neutrophil stimulation by soluble mediators, but has no effect on that released into the phagolysosome during phagocytosis. Reference: J Immunol. 1994 Mar 1;152(5):2447-55. https://www.jimmunol.org/lookup/pmidlookup?view=long&pmid=8133056
In vivo activity:
Cefdinir (FK482), a new oral cephalosporin, displayed potent oral activity versus induced infections in mice. In studies using beta-lactamase-nonproducing (beta LAC-) and -producing (beta LAC+) Staphylococcus aureus strains, respective PD50s (in mg/kg) were 11 and 24 for preventing subcutaneous abscess and 2.7 and 2.3 for preventing lethal systemic infection. In studies using beta LAC- and beta LAC+ Haemophilus influenzae, respective PD50s were 5.8 and 3.1 for preventing lethal systemic infection. Time-kill studies versus H. influenzae showed that 6- to 12-mg/kg dosing was effective in reducing viable counts of these strains in blood by > or = 100-fold by 24 h after challenge. This in vivo performance was comparable to or exceeded values generated by cefaclor, cefpodoxime proxetil, and ampicillin. Reference: Diagn Microbiol Infect Dis. 1994 Jan;18(1):41-7. https://linkinghub.elsevier.com/retrieve/pii/0732-8893(94)90132-5
Solvent mg/mL mM comments
Solubility
DMSO 33.3 84.29
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 395.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
1. Labro MT, el Benna J, Charlier N, Abdelghaffar H, Hakim J. Cefdinir (CI-983), a new oral amino-2-thiazolyl cephalosporin, inhibits human neutrophil myeloperoxidase in the extracellular medium but not the phagolysosome. J Immunol. 1994 Mar 1;152(5):2447-55. PMID: 8133056. 2. Perry CM, Scott LJ. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. Drugs. 2004;64(13):1433-64. doi: 10.2165/00003495-200464130-00004. PMID: 15212560.
In vivo protocol:
1. Cohen MA, Wold SA, Meservey MA, Gage JW, Heifetz CL, Mailloux GB, Roland GE, Yoder SL. In vivo therapeutic efficacy of cefdinir (FK482), a new oral cephalosporin, against Staphylococcus aureus and Haemophilus influenzae in mouse infection models. Diagn Microbiol Infect Dis. 1994 Jan;18(1):41-7. doi: 10.1016/0732-8893(94)90132-5. PMID: 8026156. 2. Patel S, Mandaliya D, Prajapati B, Kumar S, Seshadri S. Cefdinir Microsphere Modulated Microflora and Liver Immunological Response to Diet Induced Diabetes in Mice. Endocr Metab Immune Disord Drug Targets. 2019;19(3):349-357. doi: 10.2174/1871530319666181224122115. PMID: 30582487.
1: Chen Z, Bi X, Li J, Tang Y, Fan G, Sun D. Application and optimization of organic-inorganic hybrid monolithic capillary electrochromatography for in vivo cefdinir determination with microdialysis. J Sep Sci. 2016 Jan;39(2):440-9. doi: 10.1002/jssc.201500817. Epub 2015 Dec 11. PubMed PMID: 26549514. 2: Abou-Taleb NH, El-Wasseef DR, El-Sherbiny DT, El-Ashry SM. Optimizing the spectrofluorimetric determination of cefdinir through a Taguchi experimental design approach. Luminescence. 2015 Oct 12. doi: 10.1002/bio.3042. [Epub ahead of print] PubMed PMID: 26456088. 3: Sawant KK, Patel MH, Patel K. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. Drug Dev Ind Pharm. 2015 Nov 7:1-11. [Epub ahead of print] PubMed PMID: 26548349. 4: Liu L, Cheng F. [Analysis of the interaction between cefdinir and bovine serum albumin by spectrometry]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2015 Sep;40(9):979-86. doi: 10.11817/j.issn.1672-7347.2015.09.006. Chinese. PubMed PMID: 26408617. 5: Wang C, Li J, Feng YC, Liu Y, Hu CQ. [Construction of the quantitative structure retention relationship of cefdinir related substances]. Yao Xue Xue Bao. 2015 Sep;50(9):1161-6. Chinese. PubMed PMID: 26757554. 6: Selvi A, Das D, Das N. Potentiality of yeast Candida sp. SMN04 for degradation of cefdinir, a cephalosporin antibiotic: kinetics, enzyme analysis and biodegradation pathway. Environ Technol. 2015;36(24):3112-24. doi: 10.1080/09593330.2015.1054318. Epub 2015 Jun 17. PubMed PMID: 26000889. 7: Murphy TK, Parker-Athill EC, Lewin AB, Storch EA, Mutch PJ. Cefdinir for recent-onset pediatric neuropsychiatric disorders: a pilot randomized trial. J Child Adolesc Psychopharmacol. 2015 Feb;25(1):57-64. doi: 10.1089/cap.2014.0010. Epub 2014 Oct 9. PubMed PMID: 25299463; PubMed Central PMCID: PMC4340343. 8: Kim YC, Kim IB, Noh CK, Quach HP, Yoon IS, Chow EC, Kim M, Jin HE, Cho KH, Chung SJ, Pang KS, Maeng HJ. Effects of 1α,25-dihydroxyvitamin D3 , the natural vitamin D receptor ligand, on the pharmacokinetics of cefdinir and cefadroxil, organic anion transporter substrates, in rat. J Pharm Sci. 2014 Nov;103(11):3793-805. doi: 10.1002/jps.24195. Epub 2014 Sep 29. PubMed PMID: 25266751. 9: Selvi A, Salam JA, Das N. Biodegradation of cefdinir by a novel yeast strain, Ustilago sp. SMN03 isolated from pharmaceutical wastewater. World J Microbiol Biotechnol. 2014 Nov;30(11):2839-50. doi: 10.1007/s11274-014-1710-4. Epub 2014 Aug 3. PubMed PMID: 25086584. 10: Al-Badr AA, Alasseiri FA. Cefdinir. Profiles Drug Subst Excip Relat Methodol. 2014;39:41-112. doi: 10.1016/B978-0-12-800173-8.00002-7. Review. PubMed PMID: 24794905. 11: Jin HE, Kim IB, Kim CK, Maeng HJ. Determination of cefdinir levels in rat plasma and urine by high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral and intravenous administration of cefdinir. Biomed Chromatogr. 2013 Nov;27(11):1423-30. doi: 10.1002/bmc.2938. Epub 2013 May 28. PubMed PMID: 23712418. 12: Guo B, Zhong S, Li N, Li X, Yi J, Jin M. Dissolution enhancement of cefdinir with hydroxypropyl-β-cyclodextrin. Drug Dev Ind Pharm. 2013 Nov;39(11):1638-43. doi: 10.3109/03639045.2012.728231. PubMed PMID: 24087855. 13: Bansal S, Aggarwal G, Chandel P, Harikumar SL. Design and development of cefdinir niosomes for oral delivery. J Pharm Bioallied Sci. 2013 Oct;5(4):318-25. doi: 10.4103/0975-7406.120080. PubMed PMID: 24302841; PubMed Central PMCID: PMC3831746. 14: Roath MC, Di Palma JA. Correspondence: cefdinir and red stool. Gastroenterol Hepatol (N Y). 2013 Jun;9(6):338. PubMed PMID: 23935540; PubMed Central PMCID: PMC3736790. 15: Gouda AA, Hashem H, Hassan W. Spectophotometric methods for determination of cefdinir in pharmaceutical formulations via derivatization with 1,2-naphthoquinone-4-sulfonate and 4-chloro-7-nitrobenzo-2-oxa-1, 3-diazole. Drug Test Anal. 2012 Dec;4(12):991-1000. doi: 10.1002/dta.280. Epub 2011 Apr 28. PubMed PMID: 21538942. 16: Casey JR, Block SL, Hedrick J, Almudevar A, Pichichero ME. Comparison of amoxicillin/clavulanic acid high dose with cefdinir in the treatment of acute otitis media. Drugs. 2012 Oct 22;72(15):1991-7. doi: 10.2165/11590320-000000000-00000. PubMed PMID: 23039319; PubMed Central PMCID: PMC3963277. 17: Li J, Wang L, Chen Z, Xie R, Li Y, Hang T, Fan G. Development and validation of a rapid HPLC method for the determination of cefdinir in beagle dog plasma integrated with an automatic on-line solid-phase extraction following protein precipitation in the 96-well plate format. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 May 1;895-896:83-8. doi: 10.1016/j.jchromb.2012.03.018. Epub 2012 Mar 20. PubMed PMID: 22503733. 18: Chen J, Jiang B, Lou H, Yu L, Ruan Z. Bioequivalence evaluation of cefdinir in healthy fasting subjects. Arzneimittelforschung. 2012 Jan;62(1):9-13. doi: 10.1055/s-0031-1291361. Epub 2012 Jan 10. PubMed PMID: 22331756. 19: Khan A, Iqbal Z, Khan MI, Javed K, Khan A, Ahmad L, Shah Y, Nasir F. Simultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC/UV detection method: Method development, optimization, validation, and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 15;879(24):2423-9. doi: 10.1016/j.jchromb.2011.06.040. Epub 2011 Jul 6. PubMed PMID: 21782531. 20: Veerareddy PR, Tedla S, Banda SR, Bandari S, Jukanti R. Preparation and evaluation of mucoadhesive cefdinir microcapsules. J Adv Pharm Technol Res. 2011 Apr;2(2):115-20. doi: 10.4103/2231-4040.82955. PubMed PMID: 22171303; PubMed Central PMCID: PMC3217697.